Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverHumansAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug Combinations
Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis.
Celine Hoyek, Syed Arsalan Ahmed Naqvi, Oudai Sahvan, Fares Jamal, Kunwer Sufyan Faisal, Angelo Pirozzi, Surabhi Pathak, Diana Almader-Douglas, Mitesh J Borad, Christina Wu, Daniel H Ahn, Irbaz Bin Riaz, Tanios Bekaii-Saab, Mohamad Bassam Sonbol
Published: 202510.1016/j.dld.2025.09.024
Abstract
BACKGROUND: Patients with refractory metastatic colorectal cancer (mCRC) have poor survival outcomes. Treatment options include trifluridine/tipiracil (FTD-TPI) ± bevacizumab, regorafenib, or fruquintinib, though direct comparisons are lacking. There…
Preview only. Read the full abstract at the source